Exelixis Company

Founded in 1994, Exelixis, Inc. (Nasdaq: EXEL) is a commercially successful, oncology-focused biotechnology company that strives to accelerate the discovery, development and commercialization of new medicines for difficult-to-treat cancers.

Headquarters: United States
Funding Status: IPO
Employee Number: 251-500
Estimated Revenue: $100M to $500M
Technology: Neurological Disorders
Founded Date: 1994
Industry: Genomic and Epigenominc Instabillity